In the spectrum of the genomic EGFR alterations, from a total of 237 tumor samples tested by NGS analysis, Mehta et al. identified sixty-nine (~29%) EGFR mutated cases, of which forty-one (~59%) had the most recurrent activating EGFR mutations (approximately 22% for p.L858R and 38% for Del19). Here, EGFR is linked to neoplasm.